Cancer

Title
Risk-adapted Chemotherapy in Younger Patients with Newly Diagnosed Standard-risk Acute Lymphoblastic Leukemia
Trial Number
202998
Number of Participants
1,200
Principal Investigator

Ricarchito Manera

M.D., FAAP
Pediatric Hematology/Oncology
Professor
Eligibility

Children up to 10 years of age with newly diagnosed standard risk B-precursor acute lymphoblastic leukemia may be eligible. Specific inclusion and exclusion criteria are available from the Loyola Clinical Trials Office, (708) 216-2026.

Purpose

Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy), giving the drugs in different doses, and giving the drugs in different combinations may kill more cancer cells. Children will be placed in groups according to the results of biology testing done on the child’s bone marrow. According to these studies, the low-risk children get less intense treatment, and the higher-risk children will be treated on a high-risk study.

Enrollment

(708) 216-2026

MORE CLINICAL TRIALS

Clinical Trials

For more information call (888) LUHS-888.